The New NNRTI ACC007 Combined with Lamivudine and Tenofovir Disoproxil Fumarate Show Synergy Anti-HIV Activity In Vitro

Author(s): Xu-Sheng Huang, Rong-Hua Luo, Xiong-Lin Hu, Huan Chen, Si-Ying Xiang, Cheng-Run Tang, Chun-Tao Zhang, Xiao-Ning Shen*, Yong-Tang Zheng*

Journal Name: Current HIV Research

Volume 18 , Issue 5 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Acquired immunodeficiency syndrome can hardly be cured currently and people with human immunodeficiency virus (HIV) need lifelong treatment that may result in the emergence of drug resistance which leads to failed treatment. Thus, the development of new anti- HIV drugs and new treatment regimens are necessary.

Objective: The aim of this study is to analyze the combined anti-HIV activity of tenofovir disoproxil fumarate, lamivudine and ACC007, a new non-nucleoside reverse transcriptase inhibitor.

Methods: The antiviral activity of tenofovir disoproxil fumarate, lamivudine and ACC007 alone or in combination against different HIV-1 strains was determined by the detection of HIV-1 p24 level through enzyme-linked immunosorbent assay.

Result: ACC007 showed EC50 of nanomolar range (from 3.03 nM to 252.59 nM) against all HIV-1 strains used in this study except the HIV-1A17, with EC50 of 1.57 μM. The combined antiviral activity of ACC007, lamivudine and tenofovir disoproxil fumarate showed synergy antiviral activity against all HIV-1 strains used in this study. The three-drug combination showed moderate synergism against HIV-1A17, HIV-14755-5, HIV-1K103N and HIV-1V106M, with a combination index value ranging from 0.71 to 0.87, and showed synergism against the other HIV-1 strains with combination index value from 0.35 to 0.67. The combination with ACC007 significantly increases the dose reduction index value of lamivudine and tenofovir disoproxil fumarate, compared with two-drug combination.

Conclusion: ACC007 exhibits potent antiviral activity alone or with 3TC and TDF, and exerts synergistic effect against all HIV strains used in our investigation in vitro.

Keywords: HIV, AIDS, NNRTI, ART, ACC007, antiviral activity, drug combination, combination index.

[1]
Arruda ER Junior, Lacerda HR, Moura LC, et al. Risk factors related to hypertension among patients in a cohort living with HIV/AIDS. Braz J Infect Dis 2010; 14(3): 281-7.
[http://dx.doi.org/10.1016/S1413-8670(10)70057-X ] [PMID: 20835513]
[2]
Blanco F, San Román J, Vispo E, et al. Management of metabolic complications and cardiovascular risk in HIV-infected patients. AIDS Rev 2010; 12(4): 231-41.
[PMID: 21179187]
[3]
Gupta V, Biswas A, Sharma SK. Metabolic and body composition changes after six months of highly active antiretroviral therapy in northern Indian patients. Int J STD AIDS 2011; 22(1): 46-9.
[http://dx.doi.org/10.1258/ijsa.2010.010193 ] [PMID: 21364067]
[4]
Malaza A, Mossong J, Bärnighausen T, Newell ML. Hypertension and obesity in adults living in a high HIV prevalence rural area in South Africa. PLoS One 2012; 7(10): e47761.
[http://dx.doi.org/10.1371/journal.pone.0047761 ] [PMID: 23082211]
[5]
Nsagha DS, Assob JC, Njunda AL, et al. Risk Factors of Cardiovascular Diseases in HIV/AIDS Patients on HAART. Open AIDS J 2015; 9: 51-9.
[http://dx.doi.org/10.2174/1874613601509010051 ] [PMID: 26587072]
[6]
Palella FJ Jr, Phair JP. Cardiovascular disease in HIV infection. Curr Opin HIV AIDS 2011; 6(4): 266-71.
[http://dx.doi.org/10.1097/COH.0b013e328347876c ] [PMID: 21546831]
[7]
Pere D, Ignacio SL, Ramón T, et al. Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort. Open AIDS J 2008; 2: 26-38.
[http://dx.doi.org/10.2174/1874613600802010026 ] [PMID: 18923695]
[8]
Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24(10): 1537-48.
[PMID: 20453631]
[9]
Friis-Møller N, Weber R, Reiss P, et al. DAD study group Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17(8): 1179-93.
[http://dx.doi.org/10.1097/00002030-200305230-00010 ] [PMID: 12819520]
[10]
Mayanja BN, Kasamba I, Levin J, et al. COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort. AIDS Res Ther 2017; 14: 26.
[http://dx.doi.org/10.1186/s12981-017-0154-y ] [PMID: 28484508]
[11]
Muller EV, Gimeno SGA. Risk factors for cardiovascular disease in HIV/AIDS patients treated with highly active antiretroviral therapy (HAART) in the central-southern region of the state of Paraná - Brazil. Cien Saude Colet 2019; 24(5): 1903-14.
[http://dx.doi.org/10.1590/1413-81232018245.16682017 ] [PMID: 31166523]
[12]
Ngu RC, Choukem SP, Dimala CA, Ngu JN, Monekosso GL. Prevalence and determinants of selected cardio-metabolic risk factors among people living with HIV/AIDS and receiving care in the South West Regional Hospitals of Cameroon: a cross-sectional study. BMC Res Notes 2018; 11(1): 305.
[http://dx.doi.org/10.1186/s13104-018-3444-0 ] [PMID: 29769110]
[13]
Njelekela M, Muhihi A, Aveika A, et al. Prevalence of Hypertension and Its Associated Risk Factors among 34,111 HAART Naïve HIV-Infected Adults in Dar es Salaam, Tanzania. Int J Hypertens 2016; 2016: 5958382.
[http://dx.doi.org/10.1155/2016/5958382 ] [PMID: 27872756]
[14]
Rogalska-Płońska M, Rogalski P, Leszczyszyn-Pynka M, et al. Hypertension, dyslipidaemia, and cardiovascular risk in HIV infected adults in Poland. Kardiol Pol 2017; 75(12): 1324-31.
[http://dx.doi.org/10.5603/KP.a2017.0148 ] [PMID: 28715065]
[15]
Bloomfield GS, Leung C. Cardiac Disease Associated with Human Immunodeficiency Virus Infection. Cardiol Clin 2017; 35(1): 59-70.
[http://dx.doi.org/10.1016/j.ccl.2016.09.003 ] [PMID: 27886790]
[16]
De Socio GVL, Schillaci G. Hypertension in HIV patients. AIDS 2006; 20(12): 1682-3.
[http://dx.doi.org/10.1097/01.aids.0000238422.36313.21 ] [PMID: 16868457]
[17]
Oliveira RVC, Shimakura SE, Campos DP, et al. Effects of antiretroviral treatment and nadir CD4 count in progression to cardiovascular events and related comorbidities in a HIV Brazilian cohort: a multi-stage approach. AIDS Care 2018; 30(5): 551-9.
[http://dx.doi.org/10.1080/09540121.2017.1391984 ] [PMID: 29058481]
[18]
Tripathi A, Liese AD, Winniford MD, et al. Impact of clinical and therapeutic factors on incident cardiovascular and cerebrovascular events in a population-based cohort of HIV-infected and non-HIV infected adults. Clin Cardiol 2014; 37(9): 517-22.
[http://dx.doi.org/10.1002/clc.22311 ] [PMID: 25223811]
[19]
Dimala CA, Kadia BM, Kemah B-L, Tindong M, Choukem S-P. Association between CD4 Cell Count and Blood Pressure and Its Variation with Body Mass Index Categories in HIV-Infected Patients. Int J Hypertens 2018; 20181691474
[http://dx.doi.org/10.1155/2018/1691474] [PMID: 29610680]
[20]
León R, Reus S, Diez M, Portilla J. Undiagnosed arterial hypertension in HIV-infected patients on antiretroviral therapy. Rev Esp Quimioter 2018; 31(1): 58-9.
[PMID: 29390601]
[21]
Nduka CU, Stranges S, Bloomfield GS, et al. A plausible causal link between antiretroviral therapy and increased blood pressure in a sub-Saharan African setting: A propensity score-matched analysis Int J Cardiol 2016; 220: 400-7.
[http://dx.doi.org/10.1016/j.ijcard.2016.06.210 ] [PMID: 27390962]
[22]
Seaberg EC, Muñoz A, Lu M, et al. Multicenter AIDS Cohort Study. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19(9): 953-60.
[http://dx.doi.org/10.1097/01.aids.0000171410.76607.f8 ] [PMID: 15905677]
[23]
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Am J Clin Nutr 1998; 68(4): 899-917.
[http://dx.doi.org/10.1093/ajcn/68.4.899 ] [PMID: 9771869]
[24]
Malachias M, Plavnik FL, Machado CA, Malta D, Scala LCN, Fuchs S. 7th Brazilian Guideline of Arterial Hypertension: Chapter 1 - Concept, Epidemiology and Primary Prevention. Arq Bras Cardiol 2016; 107(3)(Suppl. 3): 1-6.
[PMID: 27819380]
[25]
Antonello VS, Antonello IC, Grossmann TK, Tovo CV, Pupo BB, Winckler Lde Q. Hypertension--an emerging cardiovascular risk factor in HIV infection. J Am Soc Hypertens 2015; 9(5): 403-7.
[http://dx.doi.org/10.1016/j.jash.2015.03.008 ] [PMID: 25979413]
[26]
Okpa HO, Bisong EM, Enang OE, Monjok E, Essien EJ. Predictors of hypertension in an urban HIV-infected population at the University of Calabar Teaching Hospital, Calabar, Nigeria. HIV AIDS (Auckl) 2017; 9: 19-24.
[http://dx.doi.org/10.2147/HIV.S126374 ] [PMID: 28243150]
[27]
Pangmekeh PJ, Awolu MM, Gustave S, Gladys T, Cumber SN. Association between highly active antiretroviral therapy (HAART) and hypertension in persons living with HIV/AIDS at the Bamenda regional hospital, Cameroon. Pan Afr Med J 2019; 33: 87.
[http://dx.doi.org/10.11604/pamj.2019.33.87.15574 ] [PMID: 31489065]
[28]
Yang CJ, Wang HY, Chou TC, Chang CJ. Prevalence and related drug cost of comorbidities in HIV-infected patients receiving highly active antiretroviral therapy in Taiwan: A cross-sectional study. J Microbiol Immunol Infect 2019; 52(5): 720-7.
[http://dx.doi.org/10.1016/j.jmii.2019.05.011 ] [PMID: 31358463]
[29]
Cade WT, Reeds DN, Mondy KE, et al. Yoga lifestyle intervention reduces blood pressure in HIV-infected adults with cardiovascular disease risk factors. HIV Med 2010; 11(6): 379-88.
[http://dx.doi.org/10.1111/j.1468-1293.2009.00801.x ] [PMID: 20059570]
[30]
De Socio GV, Ricci E, Maggi P, et al. CISAI Study Group Prevalence, awareness, treatment, and control rate of hypertension in HIV-infected patients: the HIV-HY study. Am J Hypertens 2014; 27(2): 222-8.
[http://dx.doi.org/10.1093/ajh/hpt182 ] [PMID: 24077828]
[31]
Glass TR, Ungsedhapand C, Wolbers M, et al. Swiss HIV Cohort Study. Prevalence of risk factors for cardiovascular disease in HIV infected patients over time: the Swiss HIV Cohort Study. HIV Med 2006; 7(6): 404-10.
[http://dx.doi.org/10.1111/j.1468-1293.2006.00400.x ] [PMID: 16903986]
[32]
Menanga AP, Ngomseu CK, Jingi AM, et al. Patterns of cardiovascular disease in a group of HIV-infected adults in Yaoundé, Cameroon. Cardiovasc Diagn Ther 2015; 5(6): 420-7.
[PMID: 26675421]
[33]
Rabkin M, Mutiti A, Chung C, Zhang Y, Wei Y, El-Sadr WM. Missed Opportunities to Address Cardiovascular Disease Risk Factors amongst Adults Attending an Urban HIV Clinic in South Africa. PLoS One 2015; 10(10)e0140298
[http://dx.doi.org/10.1371/journal.pone.0140298] [PMID: 26447777]
[34]
Hejazi N, Huang MSL, Lin KG, Choong LCK. Hypertension among HIV-infected adults receiving highly active antiretroviral therapy (HAART) in Malaysia. Glob J Health Sci 2013; 6(2): 58-71.
[http://dx.doi.org/10.5539/gjhs.v6n2p58 ] [PMID: 24576366]
[35]
Mateen FJ, Kanters S, Kalyesubula R, et al. Hypertension prevalence and Framingham risk score stratification in a large HIV positive cohort in Uganda. J Hypertens 2013; 31(7): 1372-8.
[http://dx.doi.org/10.1097/HJH.0b013e328360de1c ] [PMID: 23615323]
[36]
Ogunmola OJ, Oladosu OY, Olamoyegun AM. Association of hypertension and obesity with HIV and antiretroviral therapy in a rural tertiary health center in Nigeria: a cross-sectional cohort study. Vasc Health Risk Manag 2014; 10: 129-37.
[http://dx.doi.org/10.2147/VHRM.S58449 ] [PMID: 24672244]
[37]
Ataro Z, Ashenafi W, Fayera J, Abdosh T. Magnitude and associated factors of diabetes mellitus and hypertension among adult HIV-positive individuals receiving highly active antiretroviral therapy at Jugal Hospital, Harar, Ethiopia. HIV AIDS (Auckl) 2018; 10: 181-92.
[http://dx.doi.org/10.2147/HIV.S176877 ] [PMID: 30349400]
[38]
Dimala CA, Atashili J, Mbuagbaw JC, Wilfred A, Monekosso GL. Prevalence of Hypertension in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) Compared with HAART Naïve Patients at the Limbe Regional Hospital, Cameroon. PLoS One 2016; 11(2)e0148100
[http://dx.doi.org/10.1371/journal.pone.0148100] [PMID: 26862763]
[39]
Kansiime S, Mwesigire D, Mugerwa H. Prevalence of non-communicable diseases among HIV positive patients on antiretroviral therapy at joint clinical research centre, Lubowa, Uganda. PLoS One 2019; 14(8)e0221022
[http://dx.doi.org/10.1371/journal.pone.0221022] [PMID: 31398244]
[40]
Peck RN, Shedafa R, Kalluvya S, et al. Hypertension, kidney disease, HIV and antiretroviral therapy among Tanzanian adults: a cross-sectional study. BMC Med 2014; 12: 125.
[http://dx.doi.org/10.1186/s12916-014-0125-2 ] [PMID: 25070128]
[41]
Pierre S, Seo G, Rivera VR, et al. Prevalence of hypertension and cardiovascular risk factors among long-term AIDS survivors: A report from the field. J Clin Hypertens (Greenwich) 2019; 21(10): 1558-66.
[http://dx.doi.org/10.1111/jch.13663 ] [PMID: 31448551]
[42]
Edward AO, Oladayo AA, Omolola AS, Adetiloye AA, Adedayo PA. Prevalence of traditional cardiovascular risk factors and evaluation of cardiovascular risk using three risk equations in nigerians living with human immunodeficiency virus. N Am J Med Sci 2013; 5(12): 680-8.
[http://dx.doi.org/10.4103/1947-2714.123251 ] [PMID: 24404550]
[43]
Nduka CU, Stranges S, Sarki AM, Kimani PK, Uthman OA. Evidence of increased blood pressure and hypertension risk among people living with HIV on antiretroviral therapy: a systematic review with meta-analysis. J Hum Hypertens 2016; 30(6): 355-62.
[http://dx.doi.org/10.1038/jhh.2015.97 ] [PMID: 26446389]
[44]
Chireshe R, Naidoo K, Nyamakura R. Hypertension among human immunodeficiency virus infected patients on treatment at Parirenyatwa Hospital: A descriptive study. Afr J Prim Health Care Fam Med 2019; 11(1): e1-8.
[http://dx.doi.org/10.4102/phcfm.v11i1.1974 ] [PMID: 31478742]
[45]
Sattler FR, Qian D, Louie S, et al. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001; 15(15): 2001-10.
[http://dx.doi.org/10.1097/00002030-200110190-00013 ] [PMID: 11600829]
[46]
Palacios R, Santos J, García A, et al. Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIV Med 2006; 7(1): 10-5.
[http://dx.doi.org/10.1111/j.1468-1293.2005.00333.x ] [PMID: 16313287]
[47]
da Cunha GH, Franco KB, Galvão MTG, et al. Diabetes mellitus in people living with HIV/AIDS: prevalence and associated risk factors. AIDS Care 2020; 32(5): 600-7.
[http://dx.doi.org/10.1080/09540121.2019.1695727 ] [PMID: 31760760]
[48]
Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 2006; 20(7): 1019-26.
[http://dx.doi.org/10.1097/01.aids.0000222074.45372.00 ] [PMID: 16603854]
[49]
Divala OH, Amberbir A, Ismail Z, et al. The burden of hypertension, diabetes mellitus, and cardiovascular risk factors among adult Malawians in HIV care: consequences for integrated services. BMC Public Health 2016; 16(1): 1243.
[http://dx.doi.org/10.1186/s12889-016-3916-x ] [PMID: 27955664]
[50]
Muhammad S, Sani MU, Okeahialam BN. Cardiovascular disease risk factors among HIV-infected Nigerians receiving highly active antiretroviral therapy. Niger Med J 2013; 54(3): 185-90.
[http://dx.doi.org/10.4103/0300-1652.114591 ] [PMID: 23901181]
[51]
Appiah LT, Sarfo FS, Huffman MD, Nguah SB, Stiles JK. Cardiovascular risk factors among Ghanaian patients with HIV: A cross-sectional study. Clin Cardiol 2019; 42(12): 1195-201.
[http://dx.doi.org/10.1002/clc.23273 ] [PMID: 31571256]
[52]
Khunnawat C, Mukerji S, Havlichek D Jr, Touma R, Abela GS. Cardiovascular manifestations in human immunodeficiency virus infected patients. Am J Cardiol 2008; 102(5): 635-42.
[http://dx.doi.org/10.1016/j.amjcard.2008.04.035 ] [PMID: 18721528]
[53]
Lambert CT, Sandesara PB, Hirsh B, et al. HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review. HIV Med 2016; 17(6): 411-24.
[http://dx.doi.org/10.1111/hiv.12346 ] [PMID: 26611380]
[54]
Bernardino JI, Mora M, Zamora FX, et al. Hypertension and isolated office hypertension in HIV-infected patients determined by ambulatory blood pressure monitoring: prevalence and risk factors. J Acquir Immune Defic Syndr 2011; 58(1): 54-9.
[http://dx.doi.org/10.1097/QAI.0b013e3182267406 ] [PMID: 21654497]
[55]
Jung O, Bickel M, Ditting T, et al. Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity. Nephrol Dial Transplant 2004; 19(9): 2250-8.
[http://dx.doi.org/10.1093/ndt/gfh393 ] [PMID: 15238630]
[56]
Krauskopf K, Van Natta ML, Danis RP, et al. Studies of the Ocular Complications of AIDS Research Group. Correlates of hypertension in patients with AIDS in the era of highly active antiretroviral therapy. J Int Assoc Provid AIDS Care 2013; 12(5): 325-33.
[http://dx.doi.org/10.1177/2325957413491432 ] [PMID: 23764503]
[57]
Rodríguez-Díaz CE, Santiago-Rodríguez EI, Jovet-Toledo GG, et al. Comorbidities in a sample of adults with HIV in Puerto Rico: an exploratory study. HIV AIDS (Auckl) 2019; 11: 155-64.
[http://dx.doi.org/10.2147/HIV.S204985 ] [PMID: 31413642]
[58]
Torres TS, Cardoso SW, Velasque LdeS , et al. Aging with HIV: an overview of an urban cohort in Rio de Janeiro (Brazil) across decades of life. Braz J Infect Dis 2013; 17(3): 324-31.
[http://dx.doi.org/10.1016/j.bjid.2012.10.024 ] [PMID: 23602466]
[59]
Barbaro G. Pathogenesis of HIV-associated heart disease. AIDS 2003; 17(Suppl. 1): S12-20.
[http://dx.doi.org/10.1097/00002030-200304001-00003 ] [PMID: 12870526]
[60]
Costa LA, Almeida AG. Cardiovascular disease associated with human immunodeficiency virus: a review. Rev Port Cardiol 2015; 34(7-8): 479-91.
[PMID: 26162286]
[61]
Mondy KE, de las Fuentes L, Waggoner A, et al. Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV infected persons on long-term highly active antiretroviral therapy. AIDS 2008; 22(7): 849-56.
[http://dx.doi.org/10.1097/QAD.0b013e3282f70694 ] [PMID: 18427203]
[62]
Fisher SD, Kanda BS, Miller TL, Lipshultz SE. Cardiovascular disease and therapeutic drug-related cardiovascular consequences in HIV-infected patients. Am J Cardiovasc Drugs 2011; 11(6): 383-94.
[http://dx.doi.org/10.2165/11594590-000000000-00000 ] [PMID: 22149317]
[63]
Ballocca F, D’Ascenzo F, Gili S, Grosso Marra W, Gaita F. Cardiovascular disease in patients with HIV. Trends Cardiovasc Med 2017; 27(8): 558-63.
[http://dx.doi.org/10.1016/j.tcm.2017.06.005 ] [PMID: 28779949]
[64]
Gopal M, Bhaskaran A, Khalife WI, Barbagelata A. Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem. Curr Cardiol Rev 2009; 5(2): 149-54.
[http://dx.doi.org/10.2174/157340309788166705 ] [PMID: 20436855]
[65]
Ntsekhe M, Mayosi BM. Cardiac manifestations of HIV infection: an African perspective. Nat Clin Pract Cardiovasc Med 2009; 6(2): 120-7.
[http://dx.doi.org/10.1038/ncpcardio1437 ] [PMID: 19104517]
[66]
Chastain DB, Henderson H, Stover KR. Epidemiology and management of antiretroviral-associated cardiovascular disease. Open AIDS J 2015; 9: 23-37.
[http://dx.doi.org/10.2174/1874613601509010023 ] [PMID: 25866592]
[67]
Martínez E, López Bernaldo de Quirós JC, Miralles C, Podzamczer D. Considerations on the increase in blood pressure among antiretroviral-naive patients starting HAART. AIDS 2007; 21(3): 384-6.
[http://dx.doi.org/10.1097/QAD.0b013e328011daef ] [PMID: 17255753]
[68]
Duran AC, Almeida LB, Segurado AA, Jaime PC. Diet quality of persons living with HIV/AIDS on highly active antiretroviral therapy. J Hum Nutr Diet 2008; 21(4): 346-50.
[http://dx.doi.org/10.1111/j.1365-277X.2008.00886.x ] [PMID: 18721401]
[69]
Palacios R, Santos J. Blood pressure and antiretroviral therapy. AIDS 2007; 21(4): 529.
[http://dx.doi.org/10.1097/01.aids.0000260216.63560.0b ] [PMID: 17301577]
[70]
Nüesch R, Wang Q, Elzi L, et al. Swiss HIV Cohort Study. Risk of card]iovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS). J Acquir Immune Defic Syndr 2013; 62(4): 396-404.
[http://dx.doi.org/10.1097/QAI.0b013e3182847cd0 ] [PMID: 23288033]
[71]
Chow DC, Souza SA, Chen R, Richmond-Crum SM, Grandinetti A, Shikuma C. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials 2003; 4(6): 411-6.
[http://dx.doi.org/10.1310/5E7Q-PGWB-16UE-J48U ] [PMID: 14628284]
[72]
Giner-Galvañ V, Mas J, Puertoa MJ. Hipertensión arterial en pacientes infectados por el virus de la inmunodeficiencia humana Hipertens Riesgo Vasc 2003; 20: 63-70.
[http://dx.doi.org/10.1016/S1889-1837(03)71351-8 ]
[73]
Manner IW, Trøseid M, Oektedalen O, Baekken M, Os I. Low nadir CD4 cell count predicts sustained hypertension in HIV infected individuals. J Clin Hypertens (Greenwich) 2013; 15(2): 101-6.
[http://dx.doi.org/10.1111/jch.12029 ] [PMID: 23339727]
[74]
Garrison RJ, Kannel WB, Stokes J III, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987; 16(2): 235-51.
[http://dx.doi.org/10.1016/0091-7435(87)90087-9 ] [PMID: 3588564]
[75]
Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens 2010; 23(11): 1170-8.
[http://dx.doi.org/10.1038/ajh.2010.172 ] [PMID: 20706196]
[76]
Nduka CU, Uthman OA, Kimani PK, Malu AO, Stranges S. Impact of body fat changes in mediating the effects of antiretroviral therapy on blood pressure in HIV-infected persons in a sub-Saharan African setting. Infect Dis Poverty 2016; 5(1): 55.
[http://dx.doi.org/10.1186/s40249-016-0152-7 ] [PMID: 27245216]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 5
Year: 2020
Published on: 15 October, 2020
Page: [332 - 341]
Pages: 10
DOI: 10.2174/1570162X18666200620211922
Price: $65

Article Metrics

PDF: 22
HTML: 2
EPUB: 1